Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APC | P25054 | 3/20 | 0.52 |
| ▸ | CCKBR | P32239 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | FCER2 | P06734 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.46 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478149 | 0.82 | APC (0.54) | APCMMP1KEAP1QRFPRPTPN1 | |
| SCHEMBL14478103 | 0.80 | APC (0.60) | APCCCKBROPRD1OPRM1OPRK1 | |
| SCHEMBL3634638 | 0.79 | OPRD1 (0.51) | APCMMP1FCER2OPRD1OPRM1 | |
| SCHEMBL29357401 | 0.79 | APC (0.58) | APCCCKBRKEAP1QRFPROPRD1 | |
| SCHEMBL30880911 | 0.77 | NAALAD2 (0.57) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29311919 | 0.77 | KEAP1 (0.56) | APCCCKBRKEAP1OPRD1 | |
| SCHEMBL31672246 | 0.76 | LTA4H (0.55) | MMP1FCER2PTPN1 | |
| SCHEMBL31031528 | 0.75 | NAALAD2 (0.55) | OPRD1OPRM1OPRK1 | |
| SCHEMBL26464937 | 0.75 | KEAP1 (0.53) | CCKBRKEAP1OPRD1OPRM1PTPN1 | |
| SCHEMBL26464896 | 0.75 | KEAP1 (0.53) | CCKBRKEAP1OPRD1OPRM1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | PTPN5, PTPN2, PTPN4 | APC 540/4885CCKBR 3399/4885MMP1 1043/4885 |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | MAP3K20, MAP3K6, MAP3K2 | APC 780/4885CCKBR 2205/4885MMP1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.